Saturday, 28 January 2012

5th Advances Against Aspergillosis - Day 3


Saturday 28 January 2012 – Day 3 


08.00 – 08.45      Meet the Professor
                          Stump the Professor – Interesting clinical dilemmas
                          John E. Bennett, MD
                          Souha Kanj, MD


Session 9: Diagnostics and Imaging
Chairs: Dimitrios P. Kontoyiannis, MD & Malcolm Richardson, PhD

09.15 – 09.40      Application of diagnostic markers for IA in children
                          Emmanuel Roilides, MD

09.40 – 10.05      Impact of prophylaxis on galactomannan, beta-D-glucan and PCR
                          J. Peter Donnelly, PhD

10.05 – 10.30      Which antigens are important and why?
                          Max S. Topp, MD

10.30 – 10.40      Oral Poster Presentation: Impact of current antifungal therapy on PCR based investigation of bronchoalveolar lavage samples for diagnosing pulmonary aspergillosis in patients with hematologic malignanciesMark Reinwald, MD


Session 10: Pfizer Symposium
The Treatment Options Strategies for IA
Chairman: J. Peter Donnelly, PhD

11.10 – 11.15      Welcome and introduction
                          J. Peter Donnelly, PhD

11.15 – 11.30      Stratification of risk for IA in immunocompromised patients
                          Raoul Herbrecht, MD

11.20 – 11.45      Pre-emptive versus empirical anti-fungal therapy in neutropenic hematologic patients
                          Omrum Uzun, MD

11.45 – 12.00      Combination therapy: who benefits?
                          Keiren Marr, MD

12.00 – 12.10      Panel discussion


Session 11: Antifungal Resistance
Chairs: David A. Stevens, MD & Beyza Ener, MD

14.10 – 14.35      Global status of azole resistance in Europe and Asia
                          Sevtap Arikan-Akdagli, MD

14.35 – 15.00      Update on resistance mechanisms
                          David S. Perlin, PhD

15.00 – 15.10      Oral Poster Presentation: Aspergillus fumigatus biofilms releases extracellular DNA which plays a role in phase dependant antifungal resistance
                          Ranjith Rajendran, MSc

15.10 – 15.35      Current section and species complex concepts: recommendations for routine daily practice
                          Manuel Cuenca-Estrella, MD, PhD

15.35 – 16.00      Implications of resistance in Aspergillus treatment guidelines
                          Dimitrios P. Kontoyiannis, MD



16.00 – 16.10      Farewell
                          David A. Stevens, MD

16.20                  Farewell Drinks and Discussion about the next AAA Meeting


No comments:

Amazon Contextual Product Ads

Contact us at admin@aspergillus.org.uk